{
    "clinical_study": {
        "@rank": "53870", 
        "brief_summary": {
            "textblock": "RATIONALE: Antineoplastons are naturally-occurring substances that may also be made in the\n      laboratory. Antineoplastons may inhibit the growth of cancer cells.\n\n      PURPOSE: This phase II trial studies the effectiveness of antineoplaston therapy in treating\n      patients who have stage III or stage IV ovarian cancer"
        }, 
        "brief_title": "Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer", 
        "condition": "Ovarian Cancer", 
        "condition_browse": {
            "mesh_term": "Ovarian Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Study the safety and possible effectiveness of antineoplastons A10 and AS2-1 in\n           patients with incurable stage III or IV ovarian cancer.\n\n        -  Describe response to, tolerance to, and side effects of this regimen in this patient\n           population.\n\n      OUTLINE: This is an open-label study.\n\n      Patients receive gradually escalating doses of antineoplaston A10 and antineoplaston AS2-1\n      by intravenous injection 6 times daily until the maximum tolerated dose level is reached.\n\n      Treatment continues for at least 3 months in the absence of unacceptable toxicity or disease\n      progression. Patients achieving complete response (CR) continue treatment for an additional\n      8 months after achieving CR.\n\n      Tumors are measured every 2 months for 1 year and then every 3 months for 1 year.\n\n      PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed stage III or IV epithelial or germ cell ovarian cancer that\n             is unlikely to respond to existing therapy and for which no curative therapy exists\n\n          -  Measurable disease by CT scan or MRI\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  Karnofsky 60-100%\n\n        Life expectancy:\n\n          -  At least 2 months\n\n        Hematopoietic:\n\n          -  WBC at least 2,000/mm^3\n\n          -  Platelet count at least 50,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin no greater than 2.5 mg/dL\n\n          -  SGOT/SGPT no greater than 5 times upper limit of normal\n\n          -  No hepatic failure\n\n        Renal:\n\n          -  Creatinine no greater than 2.5 mg/mL\n\n          -  No renal insufficiency\n\n          -  No history of renal conditions that contraindicate high dosages of sodium\n\n        Cardiovascular:\n\n          -  No uncontrolled hypertension\n\n          -  No history of congestive heart failure\n\n          -  No other cardiovascular conditions that contraindicate high dosages of sodium\n\n        Pulmonary:\n\n          -  No serious lung disease (e.g., chronic obstructive pulmonary disease)\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception for 4 weeks before, during, and for\n             4 weeks after study participation\n\n          -  No active infection\n\n          -  No concurrent serious systemic disease\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  At least 4 weeks since prior immunotherapy and recovered\n\n          -  No concurrent immunomodulating agents\n\n        Chemotherapy:\n\n          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n\n        Endocrine therapy:\n\n          -  Concurrent corticosteroids allowed (e.g., dexamethasone or methylprednisone)\n\n        Radiotherapy:\n\n          -  At least 8 weeks since prior radiotherapy and recovered\n\n        Surgery:\n\n          -  Recovered from prior surgery\n\n        Other:\n\n          -  Prior cytodifferentiating agents allowed\n\n          -  No prior antineoplaston therapy\n\n          -  No other concurrent antineoplastic agents"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003532", 
            "org_study_id": "CDR0000066579", 
            "secondary_id": "BC-OV-2"
        }, 
        "intervention": [
            {
                "intervention_name": "antineoplaston A10", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "antineoplaston AS2-1", 
                "intervention_type": "Drug"
            }
        ], 
        "keyword": [
            "stage III ovarian epithelial cancer", 
            "stage IV ovarian epithelial cancer", 
            "recurrent ovarian epithelial cancer", 
            "stage III ovarian germ cell tumor", 
            "stage IV ovarian germ cell tumor", 
            "recurrent ovarian germ cell tumor"
        ], 
        "lastchanged_date": "July 23, 2008", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/BC-OV-2"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77055-6330"
                }, 
                "name": "Burzynski Clinic"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Carcinoma of the Ovary", 
        "overall_official": {
            "affiliation": "Burzynski Research Institute", 
            "last_name": "Stanislaw R. Burzynski, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003532"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Burzynski Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 1998", 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2004"
    }, 
    "geocoordinates": {
        "Burzynski Clinic": "29.76 -95.369"
    }
}